[WSJ] [Bloomberg] [Pharmaletter]
EPO last Friday revokes EP1020461, which covers magnesium salt of Esomeprazole and it is divisional patent of EP0652872 (product patent). ’461 patent revocation status not yet updated in European patent register. ’461 patent was opposed by many companies including Teva, Hexal, Lupin etc. Esomeprazole’s product patent (’872) has already been revoked in Europe. Astrazeneca appealed this decision.
… After the patent was granted in 2009, AstraZeneca has enforced this patent in several countries in Europe. We will continue to decide on a case by case basis whether it is appropriate to continue to assert this patent,” the spokeswoman said …
… Several generic drugmakers launched cheap copies of Nexium in Germany in late 2010, and AstraZeneca said in October that a generic had also gone on sale in Spain …
Pingback: Does Anyone Want Axanum? | Pharma Marketer